Alan Kivitz

19.7k total citations · 10 hit papers
266 papers, 12.8k citations indexed

About

Alan Kivitz is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Alan Kivitz has authored 266 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Rheumatology, 97 papers in Immunology and 77 papers in Hematology. Recurrent topics in Alan Kivitz's work include Rheumatoid Arthritis Research and Therapies (134 papers), Autoimmune and Inflammatory Disorders Research (66 papers) and Spondyloarthritis Studies and Treatments (60 papers). Alan Kivitz is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (134 papers), Autoimmune and Inflammatory Disorders Research (66 papers) and Spondyloarthritis Studies and Treatments (60 papers). Alan Kivitz collaborates with scholars based in United States, Germany and United Kingdom. Alan Kivitz's co-authors include Désirée van der Heijde, Stanley Cohen, Philip J. Mease, Jürgen Braun, Francis X. Burch, Maxime Dougados, Wayne Tsuji, Roy Fleischmann, John C. Davis and Mark C. Genovese and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Alan Kivitz

256 papers receiving 12.4k citations

Hit Papers

Denosumab in Postmenopausal Women with Low Bone Mineral D... 1999 2026 2008 2017 2006 2004 2006 1999 2003 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Denosumab in Postmenopausal Women with Low Bone Mineral Density
    2006 886 citations Michael R. McClung, E. Michael Lewiecki et al. profile →
  2. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
    2004 697 citations Philip J. Mease, Alan Kivitz et al. profile →
  3. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
    2006 660 citations Désirée van der Heijde, Alan Kivitz et al. profile →
  4. Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis
    1999 636 citations Alan Kivitz, William W. Zhao et al. profile →
  5. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
    2003 583 citations Désirée van der Heijde, Maxime Dougados et al. profile →
  6. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study
    2009 414 citations Alan Kivitz et al. profile →
  7. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
    2018 294 citations Gerd R Burmester, Joel M. Kremer et al. profile →
  8. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
    2021 163 citations Alan Kivitz, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  9. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
    2022 134 citations Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →
  10. A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
    2023 74 citations Edit Drescher, Alan Kivitz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Kivitz United States 60 7.4k 4.5k 3.3k 2.0k 1.9k 266 12.8k
Barry Bresnihan Ireland 65 7.3k 1.0× 4.0k 0.9× 2.3k 0.7× 2.6k 1.3× 1.5k 0.8× 233 12.9k
Oliver FitzGerald Ireland 66 8.7k 1.2× 6.9k 1.5× 3.9k 1.2× 2.2k 1.1× 1.1k 0.6× 471 14.6k
Douglas J. Veale Ireland 64 6.4k 0.9× 4.3k 1.0× 2.2k 0.7× 3.0k 1.5× 1.5k 0.8× 289 13.1k
Willem F. Lems Netherlands 68 8.5k 1.1× 1.8k 0.4× 1.7k 0.5× 2.8k 1.4× 2.2k 1.2× 406 15.1k
Zoltán Szekanecz Hungary 63 5.6k 0.8× 3.4k 0.8× 1.2k 0.4× 2.3k 1.2× 1.5k 0.8× 326 12.1k
Christopher T. Ritchlin United States 61 10.1k 1.4× 9.6k 2.1× 5.4k 1.6× 2.0k 1.0× 1.7k 0.9× 347 15.3k
Michel Malaise Belgium 46 4.2k 0.6× 1.6k 0.3× 1.4k 0.4× 1.9k 1.0× 700 0.4× 202 8.5k
Yeong Wook Song South Korea 46 4.2k 0.6× 2.1k 0.5× 1.0k 0.3× 1.6k 0.8× 972 0.5× 309 8.3k
F. C. Breedveld Netherlands 52 6.9k 0.9× 2.2k 0.5× 2.5k 0.7× 1.0k 0.5× 887 0.5× 119 10.2k
David H. Neustadt United States 15 12.6k 1.7× 3.5k 0.8× 3.4k 1.0× 1.9k 0.9× 1.5k 0.8× 35 17.5k

Countries citing papers authored by Alan Kivitz

Since Specialization
Citations

This map shows the geographic impact of Alan Kivitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Kivitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Kivitz more than expected).

Fields of papers citing papers by Alan Kivitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Kivitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Kivitz. The network helps show where Alan Kivitz may publish in the future.

Co-authorship network of co-authors of Alan Kivitz

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Kivitz. A scholar is included among the top collaborators of Alan Kivitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Kivitz. Alan Kivitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2025). Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials. Rheumatology and Therapy. 12(6). 1103–1123.
2.
McInnes, Iain B., Laura C. Coates, Philip J. Mease, et al.. (2025). Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nature Medicine. 31(12). 4160–4171. 1 indexed citations
3.
Buttgereit, Frank, Atul Singhal, Alan Kivitz, et al.. (2025). Efficacy and Safety of ABBV ‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial. Arthritis & Rheumatology. 77(12). 1673–1681.
4.
Kivitz, Alan, Xenofon Baraliakos, Arthur Kavanaugh, et al.. (2025). Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study. Annals of the Rheumatic Diseases. 84(10). 1660–1674. 2 indexed citations
5.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2024). Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and Therapy. 11(3). 633–648. 9 indexed citations
6.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2024). Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial. SKIN The Journal of Cutaneous Medicine. 8(6). s446–s446.
7.
Jeka, Sławomir, Eva Dokoupilová, Alan Kivitz, et al.. (2024). Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. Journal of Bone and Mineral Research. 39(3). 202–210. 6 indexed citations
8.
Burmester, Gerd R, Filip Van den Bosch, John Tesser, et al.. (2024). Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of Rheumatology. 51(7). 663–672. 3 indexed citations
9.
10.
11.
Kivitz, Alan, Alvin F. Wells, Herbert S. B. Baraf, et al.. (2023). Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Rheumatology and Therapy. 10(4). 901–915. 3 indexed citations
12.
Baker, Matthew, Sarah Kavanagh, Stanley Cohen, et al.. (2023). A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. Arthritis & Rheumatology. 75(12). 2107–2115. 14 indexed citations
13.
Dua, Anisha B., Stefano Fiore, Dimitrios A. Pappas, et al.. (2023). Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study. Rheumatology and Therapy. 10(6). 1753–1768. 1 indexed citations
14.
15.
Kivitz, Alan, et al.. (2022). Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nature Communications. 13(1). 272–272. 40 indexed citations
16.
Heijde, Désirée van der, Lianne S. Gensler, Atul Deodhar, et al.. (2020). Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases. 79(5). 595–604. 97 indexed citations
17.
Dakin, Paula, Alan Kivitz, Joseph Gimbel, et al.. (2020). Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial. Annals of the Rheumatic Diseases. 80(4). 509–517. 26 indexed citations
18.
Orwoll, Eric, Bente Langdahl, R. Chapurlat, et al.. (2011). A phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO. Open Repository and Bibliography (University of Liège). 1 indexed citations
19.
McClung, Michael R., E. Michael Lewiecki, Stanley Cohen, et al.. (2006). Denosumab in Postmenopausal Women With Low Bone Mineral Density. Obstetrical & Gynecological Survey. 61(6). 384–386. 16 indexed citations
20.
Kivitz, Alan, et al.. (2002). Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.. PubMed. 51(6). 530–7. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barry Bresnihan Breakdown of academic impact, for papers by Oliver FitzGerald Breakdown of academic impact, for papers by Douglas J. Veale Breakdown of academic impact, for papers by Willem F. Lems Breakdown of academic impact, for papers by Zoltán Szekanecz Breakdown of academic impact, for papers by Christopher T. Ritchlin Breakdown of academic impact, for papers by Michel Malaise Breakdown of academic impact, for papers by Yeong Wook Song Breakdown of academic impact, for papers by F. C. Breedveld Breakdown of academic impact, for papers by David H. Neustadt
Rankless by CCL
2026